LOGIN
ID
PW
MemberShip
2025-09-04 12:56
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
"Winrevair, gamechanger for pulmonary arterial hypertension"
by
Whang, byung-woo
Aug 18, 2025 06:01am
Winrevair (sotatercept), a new mechanism treatment for pulmonary arterial hypertension that has emerged after over 20 years, has been approved in Korea. Consequently, competitive market is expected. Although reimbursement remains a challenge, it is expected to change the treatment paradigm for pulmonary hypertension, a disease with significan
Company
Imfinzi denied reimb for bile duct cancer for the 3rd year
by
Eo, Yun-Ho
Aug 14, 2025 06:13am
Attention is focused on whether there will be progress in the reimbursement process for Imfinzi for bile duct cancer, which has remained non-reimbursed for three years now. According to industry sources, the Health Insurance Review and Assessement Service's Drug Reimbursement Evaluation Committee may likely review the agenda of expanding
Company
"A paradigm shift in atopic dermatitis treatment"¡¦ Adtralza
by
Whang, byung-woo
Aug 14, 2025 06:13am
The treatment landscape is undergoing significant changes as new drugs for atopic dermatitis, including biologics and JAK inhibitors, have emerged over the past few years. Experts assess that patients who gave up on receiving treatments due to recurrence and side effects are revisiting hospitals with the introduction of new drugs. As treat
Company
Only Vemlidy¡¯s sales grew in the ₩300B HBV drug mkt
by
Kim, Jin-Gu
Aug 14, 2025 06:13am
Korea's hepatitis B treatment market, which is valued at KRW 300 billion annually, is rapidly restructuring around Vemlidy (tenofovir alafenamide). Among original products, only Vemlidy is maintaining its growth, and in the generic market, only the Vemlidy series has shown a significant increase in sales. HBV treatment market reaches KRW
Policy
Gilead¡¯s Yescarta approved in KOR...3rd CAR-T therapy
by
Lee, Hye-Kyung
Aug 14, 2025 06:13am
The third CAR-T therapy has been approved in Korea. The Ministry of Food and Drug Safety approved Gilead Sciences Korea's Yescarta (axicabtagene ciloleucel) today (13th). Yescarta is a CAR-T therapy that received approval from the U.S. FDA in 2017 and the European EMA in 2018. Last year, the EMA approved it as a second-line treatment f
Company
'Tevimbra' applies for reimbursement for five indications
by
Eo, Yun-Ho
Aug 13, 2025 06:07am
'Tevimbra' is quickly expanding following its successful inclusion in the insurance reimbursement for esophageal cancer. BeOneMedicines Korea has been confirmed to have applied for reimbursement on the day of approval for five new indications for its PD-1 inhibitor immunotherapy Tevimbra (tislelizumab), which received additional approval
Policy
New drug approval fees ₩410mil in KOR
by
Lee, Hye-Kyung
Aug 13, 2025 06:07am
Since the new drug approval fee was significantly increased to KRW 410 million starting this year, a total of 14 new products containing 10 ingredients have been submitted for approval. Although the specific product names cannot be disclosed, dedicated teams have been formed for 6 chemical drug substances and four biopharmaceutical substances, a
Product
Mounjaro set to hit shelves next week... pricing a dilemma
by
Jung, Heung-Jun
Aug 13, 2025 06:07am
With the imminent arrival of the diabetes and obesity treatment Mounjaro (tirzepatide) in Korea, pharmacies are struggling to set an appropriate price for the item. Due to the nature of high-priced non-reimbursable drugs, there are regional price differences, and price competition is expected in the future, so pharmacies are showing a
Company
Adult vaccination in a super-aged society highlighted
by
Whang, byung-woo
Aug 13, 2025 06:07am
South Korea has entered a super-aged society, with its population aged 65 and over exceeding 20%. The need for a response through adult vaccination is being emphasized. With the number of National Immunization Program (NIP) vaccines for adults limited to just influenza and pneumococcal vaccines, there is a growing opinion that the program nee
Product
Wegovy supply price cut by 40%... to counter Mounjaro
by
Kang, Hye-Kyung
Aug 13, 2025 06:06am
The supply price for Wegovy will be reduced by approximately 40% starting on the 14th. Refund measures are also expected to be implemented for pharmacies with inventory. Novo Nordisk notified pharmacies and other relevant parties of the changes through Julic and other channels. According to Dailypharm's coverage, the prices for four dosa
1
2
3
4
5
6
7
8
9
10
>